scholarly journals Exploratory Analysis of Clinical Prognostic Factors in Patients with Advanced Cancer Using Computational Text Mining of Routine Digitised Oncology Correspondence

2018 ◽  
Vol 48 ◽  
pp. 8-8
Keyword(s):  
Prognostic Factors ◽  
Text Mining ◽  
Advanced Cancer ◽  
Exploratory Analysis

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

2018 ◽  
Vol 24 (4) ◽  
pp. 454-459 ◽  
Author(s):  
Shuji Hiramoto ◽  
Tomoko Tamaki ◽  
Kengo Nagashima ◽  
Tetsuo Hori ◽  
Ayako Kikuchi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
End Of Life ◽  
Advanced Cancer

scholarly journals Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations—A Study by the Steering Committee of the European Association for Palliative Care

2005 ◽  
Vol 23 (25) ◽  
pp. 6240-6248 ◽  
Author(s):  
Marco Maltoni ◽  
Augusto Caraceni ◽  
Cinzia Brunelli ◽  
Bert Broeckaert ◽  
Nicholas Christakis ◽  
...  
Keyword(s):  
Palliative Care ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
European Association ◽  
Prognostic Scores ◽  
Evidence Based ◽  
Advanced Cancer Patients ◽  
Clinical Recommendations ◽  
Biologic Factors

PurposeTo offer evidence-based clinical recommendations concerning prognosis in advanced cancer patients.MethodsA Working Group of the Research Network of the European Association for Palliative Care identified clinically significant topics, reviewed the studies, and assigned the level of evidence. A formal meta-analysis was not feasible because of the heterogeneity of published studies and the lack of minimal standards in reporting results. A systematic electronic literature search within the main available medical literature databases was performed for each of the following four areas identified: clinical prediction of survival (CPS), biologic factors, clinical signs and symptoms and psychosocial variables, and prognostic scores. Only studies on patients with advanced cancer and survival ≤ 90 days were included.ResultsA total of 38 studies were evaluated. Level A evidence-based recommendations of prognostic correlation could be formulated for CPS (albeit with a series of limitations of which clinicians must be aware) and prognostic scores. Recommendations on the use of other prognostic factors, such as performance status, symptoms associated with cancer anorexia-cachexia syndrome (weight loss, anorexia, dysphagia, and xerostomia), dyspnea, delirium, and some biologic factors (leukocytosis, lymphocytopenia, and C-reactive protein), reached level B.ConclusionPrognostication of life expectancy is a significant clinical commitment for clinicians involved in oncology and palliative care. More accurate prognostication is feasible and can be achieved by combining clinical experience and evidence from the literature. Using and communicating prognostic information should be part of a multidisciplinary palliative care approach.

scholarly journals Delaying ACL reconstruction and treating with exercise therapy alone may alter prognostic factors for 5-year outcome: an exploratory analysis of the KANON trial

2017 ◽  
Vol 51 (22) ◽  
pp. 1622-1629 ◽  
Author(s):  
Stephanie R Filbay ◽  
Ewa M Roos ◽  
Richard B Frobell ◽  
Frank Roemer ◽  
Jonas Ranstam ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Prognostic Factor ◽  
Exercise Therapy ◽  
Exploratory Analysis ◽  
Acl Rupture ◽  
Link Type ◽  
Acl Surgery ◽  
Patient Reported ◽  
Early Reconstruction ◽  
Delayed Reconstruction

AimIdentify injury-related, patient-reported and treatment-related prognostic factors for 5-year outcomes in acutely ACL-ruptured individuals managed with early reconstruction plus exercise therapy, exercise therapy plus delayed reconstruction or exercise therapy alone.MethodsExploratory analysis of the Knee Anterior Cruciate Ligament, Nonsurgical versus Surgical Treatment (KANON) trial (ISRCTN84752559). Relationships between prognostic factors (baseline cartilage, meniscus and osteochondral damage, baseline extension deficit, baseline patient-reported outcomes, number of rehabilitation visits, graft/contralateral ACL rupture, non-ACL surgery and ACL treatment strategy) and 5-year Knee Injury and Osteoarthritis Outcome Score (KOOS) pain, symptoms, sport/recreation and quality of life (QOL) scores were explored using multivariable linear regression. Estimates were adjusted for sex, age, body mass index, preinjury activity level, education and smoking.ResultsFor all participants (n=118), graft/contralateral ACL rupture, non-ACL surgery and worse baseline 36-item Short-Form Mental Component Scores were associated with worse outcomes. Treatment with exercise therapy alone was a prognostic factor forlessknee symptoms compared with early reconstruction plus exercise therapy (regression coefficient 10.1, 95% CI 2.3 to 17.9). Baseline meniscus lesion was associated with worse sport/recreation function (−14.4, 95% CI −27.6 to –1.3) and osteochondral lesions were associated with worse QOL (−12.3, 95% CI −24.3 to –0.4) following early reconstruction plus exercise therapy. In the same group, undergoing additional non-ACL surgery and worse baseline KOOS scores were prognostic for worse outcome on all KOOS subscales. Following delayed reconstruction, baseline meniscus damage was a prognostic factor forlesspain (14.3, 95% CI 0.7 to 27.9). Following exercise therapy alone, undergoing non-ACL surgery was prognostic for worse pain.ConclusionsTreatment-dependent differences in prognostic factors for 5-year outcomes may support individualised treatment after acute ACL rupture in young active individuals.Trial registration numberCurrent Controlled TrialsISRCTN84752559.

QTc interval in advanced cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20658-e20658
Author(s):  
D. Trivanovic ◽  
R. Dobrila-Dintinjana ◽  
Z. Mavric ◽  
D. Stimac ◽  
M. Petkovic
Keyword(s):  
Prognostic Factors ◽  
Advanced Cancer ◽  
Median Survival ◽  
Cardiac Disease ◽  
Group Performance ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Solid Cancer ◽  
Qtc Interval ◽  
One Year

e20658 Background: The purpose is to identify prognostic factors that may have impact on survival in patients with advanced cancer. Methods: We retrospectively reviewed the data of patients who had biopsy proven advanced solid cancer disease in stage IV and no history or evidence of any prior cardiac disease. Univariate and multivariate stepwise Cox proportional hazard regression analysis were performed to identify independent predictors of one year survival. Results: Between 1/01 and 9/05, 143 patients (83 male and 60 female) with advanced cancers were evaluated in our institution. The primary site of disease was lung (28%), pancreas (19%), colon (15%), rectum (13%), breast (12%), and other (13%). The median follow-up was 12,5 months, median overall survival (OS) was 8.1 months, and 1-year OS rate was 62%. Median age was 65 years. OS was significantly related to the following pre-treatment prognostic factors: Age ≥65 (years), anaemia (hemoglobin level <13.2 g/dl), Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1, and prolonged QTc interval in electrocardiogram (ECG). However, multivariate analysis revealed only prolonged QTc as independent prognostic parameter with 1-y survival status. Using 440 ms as the cut off value, the QTc interval was prolonged in 32 patients (22%) with median survival of 45 days and normal in 111 patients (78%) with median survival of 280 days. During the one-year 25 patients (78%) died in group with prolonged QTc interval while in group with normal QTc interval died 63 patients (57%). Conclusions: The results of our study indicate that a prolonged QTc interval (> 440 ms) is an adverse prognostic sign in patients with advanced cancer and without cardiac disease which correlates with increased mortality rates within one year after the diagnosis. Our findings suggest that QTc prolongation may be a good adjunct in risk stratification of patients with advanced cancer who are being considered for aggressive treatment regimens. [Table: see text] No significant financial relationships to disclose.

Exploratory analysis of trifluridine/tipiracil in late-stage metastatic colorectal cancer (mCRC): Prognostic factors.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 24-24
Author(s):  
Meinolf Karthaus ◽  
B Hoell ◽  
G Zaun ◽  
M Guyot ◽  
Martin H. Schuler ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Liver Metastases ◽  
Real World ◽  
Survival Data ◽  
Late Stage ◽  
Good Prognosis ◽  
Exploratory Analysis ◽  
The Real ◽  
Real World Setting ◽  
Time Since Diagnosis

24 Background: Trifluridine/Tipiracil (FTD/TPI) is effective in pts with refractory mCRC. Enrollment into in the RECOURSE trial was allowed only for pts with ECOG < 1 pts, while real world pts may have a lower ECOG. In addition, predictive markers for the efficacy of FTD/TPI at late stage are open. This exploratory analysis assessed outcome of mCRC pts (including ECOG PS ≥ 2) upon FTD/TPI treatment by prognostic factors in the real world setting. Methods: This cohort included mCRC pts who were treated with FTD/TPI from 01/2016 until 08/2019 at two large volume CRC centers in Germany. Pts were classified with good prognosis characteristics (GPC) according to Tabernero et al. (abstract 677, ASCO-GI 2019) defined by 1 or 2 metastatic sites and time since diagnosis of first metastases ≥ 18 mo. Pts of this group without liver metastases had the best prognostic characteristics. Pts with poor prognostic characteristics (PPC) were characterized by ≥ 3 metastases sites and time since diagnosis of first metastases ≤ 18 mo. Results: A total of 44 mCRC pts were included in this analysis (mean age 62.5 yrs; 22 males and 22 females). Within the GPC population (n=28; median age 67 yrs; KRAS wt n= 21; KRAS mt n= 7; ECOG 0-1 n= 23; ECOG ≥ 2n=7) 6 pts were alive up to 08/2019 and 4 were lost to FU. Four pts of the GPC were without liver metastases. Within the PPC group (n=16; median age 59 yrs; KRAS wt n= 6; KRAS mt n= 10; ECOG 0-1 n= 15; ECOG ≥ 2 n=1) 2 pts were alive and 2 were lost to FU. The mPFS and mOS of the GPC group (n=18) were 2,15 mo (range 0,62-10,13) and 4,63 mo (range 0,95-14,39), respectively. The mPFS and mOS of the PPC group (n=12) were 1,31 mo (range 0,76-9,72) and 4,72 mo (range 0,76-16,61), respectively. Pts with an ECOG ≥ 2 had a mOS of 2,76 mo (range 0,95-6,92), and a mPFS 1,67 mo (range 0,53-1,77). Conclusions: GPC and PPC group pts treated with FTD/TPI differed with respect to mPFS, but these pts had a comparable mOS in the real world setting. PFS and OS were lower when compared to the Tabernero analysis of the RECOURSE trial, which may reflect the real world setting. Inclusion of pts with an ECOG of ≥ 2 was feasible but showed poor survival data in the third line. Nevertheless, all pts with mCRC benefited from FTD/TPI treatment.

Sign in / Sign up

Export Citation Format

Share Document